RxDoctor Payments Data

Joseph Marra, OD

Corneal and Contact Management · Toledo, OHNPI 1831194869

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $775 of the $878 with a category attached, or 88.3%. It is spread thinly across 12 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $272 and has fallen 57.8% since, to $115 in 2025.

$878in general payments, 2019–2025

Across 32 payments — averaging $27.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optos, Inc.$166
  • Bausch & Lomb Americas Inc.$131
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$109
  • Coopervision Inc.$96
  • Biotissue Holdings Inc.$92
  • Alcon$61
  • plus $223 from 6 others

What the payments were for

  • Food & beverage$77588%
  • Entertainment$10312%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$878 in reported general payments places this provider in the 70th percentile of 40 corneal and contact management providers in Ohio.

See all corneal and contact management providers in Ohio

Medicare billing

Part B allowed, 2024
$48,374
Medicare patients
420
Services billed
2,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast12$18,696
RestasisCyclosporine14$13,790
Cyclosporine12$6,518
VyzultaLatanoprostene Bunod13$6,362
Latanoprost433$2,777
Prednisolone Acetate37$1,067
Tobramycin-DexamethasoneTobramycin/Dexamethasone13$573
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat41$557
Dorzolamide Hcl25$508
Timolol Maleate61$403
Doxycycline Hyclate14$143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$131$25,05825 claims
AbbVieRestasis$54$13,79014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 40 corneal and contact management providers in Ohio.

Other corneal and contact management in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →